Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 4, 2018 | IPO | $237.50M | — | — | — | Detail |
Aug 6, 2018 | Series Unknown | — | 1 | — | — | Detail |
Jul 16, 2018 | Secondary Market | — | 2 | — | — | Detail |
May 11, 2017 | Series E | $360M | 9 | SoftBank Vision Fund | — | Detail |
Jan 7, 2016 | Series D | $100M | 10 | OrbiMed | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SoftBank Vision Fund | Yes | Series E |
Plug and Play | — | Series Unknown |
EquityZen | — | Secondary Market |
Storm Global | — | Secondary Market |
Sequoia Capital | — | Series E |
8VC | — | Series E |
C.M. Capital Advisors | — | Series E |
Khosla Ventures | — | Series E |
Lightspeed Venture Partners | — | Series E |
OrbiMed | — | Series E |
Guardant Health has acquired 1 organizations. Their most recent acquisition was Bellwether Bio on Mar 28, 2019. They acquired Bellwether Bio for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Mar 28, 2019
Bellwether Bio
|
Biotechnology | acquisition | — | Detail |